TY - JOUR
T1 - Differential burden of rare protein truncating variants in Alzheimer's disease patients compared to centenarians
AU - T2D-GENES Consortium
AU - Freudenberg-Hua, Yun
AU - Li, Wentian
AU - Abhyankar, Avinash
AU - Vacic, Vladimir
AU - Cortes, Vanessa
AU - Ben-Avraham, Danny
AU - Koppel, Jeremy
AU - Greenwald, Blaine
AU - Germer, Soren
AU - Darnell, Robert B.
AU - Barzilai, Nir
AU - Freudenberg, Jan
AU - Atzmon, Gil
AU - Davies, Peter
N1 - Publisher Copyright:
© The Author 2016.
PY - 2016
Y1 - 2016
N2 - We compared coding region variants of 53 cognitively healthy centenarians and 45 patients with Alzheimer's disease (AD), all of Ashkenazi Jewish (AJ) ancestry. Despite the small sample size, the known AD risk variant APOE4 reached genome-wide significance, indicating the advantage of utilizing 'super-controls'. We restricted our subsequent analysis to rare variants observed at most once in the 1000 Genomes database and having a minor allele frequency below 2% in our AJ sample. We compared the burden of predicted protein altering variants between cases and controls as normalized by the level of rare synonymous variants. We observed an increased burden among AD subjects for predicted loss-of-function (LoFs) variants defined as stop-gain, frame shift, initiation codon (INIT) and splice site mutations (n=930, OR=1.3, P=1.5×E-5). There was no enrichment across all rare protein altering variants defined as missense plus LoFs, in frame indels and stop-loss variants (n=13 014, OR=0.97, P=0.47). Among LoFs, the strongest burden was observed for INIT (OR=2.16, P=0.0097) and premature stop variants predicted to cause non-sense-mediated decay in the majority of transcripts (NMD) (OR=1.98, P=0.02). Notably, this increased burden of NMD, INIT and splice variants was more pronounced in a set of 1397 innate immune genes (OR=4.55, P=0.0043). Further comparison to additional exomes indicates that the difference in LoF burden originated both from the AD and centenarian sample. In summary, we observed an overall increased burden of rare LoFs in AD subjects as compared to centenarians, and this enrichment is more pronounced for innate immune genes.
AB - We compared coding region variants of 53 cognitively healthy centenarians and 45 patients with Alzheimer's disease (AD), all of Ashkenazi Jewish (AJ) ancestry. Despite the small sample size, the known AD risk variant APOE4 reached genome-wide significance, indicating the advantage of utilizing 'super-controls'. We restricted our subsequent analysis to rare variants observed at most once in the 1000 Genomes database and having a minor allele frequency below 2% in our AJ sample. We compared the burden of predicted protein altering variants between cases and controls as normalized by the level of rare synonymous variants. We observed an increased burden among AD subjects for predicted loss-of-function (LoFs) variants defined as stop-gain, frame shift, initiation codon (INIT) and splice site mutations (n=930, OR=1.3, P=1.5×E-5). There was no enrichment across all rare protein altering variants defined as missense plus LoFs, in frame indels and stop-loss variants (n=13 014, OR=0.97, P=0.47). Among LoFs, the strongest burden was observed for INIT (OR=2.16, P=0.0097) and premature stop variants predicted to cause non-sense-mediated decay in the majority of transcripts (NMD) (OR=1.98, P=0.02). Notably, this increased burden of NMD, INIT and splice variants was more pronounced in a set of 1397 innate immune genes (OR=4.55, P=0.0043). Further comparison to additional exomes indicates that the difference in LoF burden originated both from the AD and centenarian sample. In summary, we observed an overall increased burden of rare LoFs in AD subjects as compared to centenarians, and this enrichment is more pronounced for innate immune genes.
UR - http://www.scopus.com/inward/record.url?scp=85016106926&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddw150
DO - 10.1093/hmg/ddw150
M3 - Article
C2 - 27260402
AN - SCOPUS:85016106926
SN - 0964-6906
VL - 25
SP - 3096
EP - 3105
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 14
ER -